Phase II Trial of Carboplatin in Soft-Tissue Sarcoma
| Autor: | R. L. Comis, David Goldstein, D. C. Tormey, M. Shiraki, Ernest C Borden, J. E. Harris, B. Cheuvart, D. L. Trump |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Alpha interferon Soft Tissue Neoplasms Gastroenterology Carboplatin chemistry.chemical_compound Internal medicine medicine Humans Doxorubicin Aged Chemotherapy business.industry Soft tissue sarcoma Remission Induction Sarcoma Middle Aged medicine.disease Chemotherapy regimen United States Confidence interval Surgery Oncology chemistry Drug Evaluation Female business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 13:420-423 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199010000-00011 |
| Popis: | As part of the Eastern Cooperative Oncology Group program for the assessment of new drugs in sarcomas, a Phase II trial of carboplatin was performed in patients who had received no more than one prior chemotherapy regimen. A total of 50 patients received either 400 mg/m2 or 320 mg/m2 depending on whether they had received prior radiotherapy. A response rate of 16% (95% confidence interval 6-32%) occurred in the 37 patients who had received doxorubicin as their only prior systemic therapy. Three of the six responses were complete and persisted for 7 to 34 months. In contrast none of the 13 patients who received carboplatin after initial progression on doxorubicin and subsequent progression on interferon alpha responded. The overall response rate was therefore 12% (95% confidence interval 5-24%). Toxicity was primarily hematologic, with 14 patients having Eastern Cooperative Oncology Group (ECOG) grade 3 toxicity and no grade 4 or 5 toxicities. In view of the number of complete responses, carboplatin should be studied further in untreated patients with advanced soft tissue sarcoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|